Novel Pd Marker for Histone Deacetylase Inhibitor
AssigneeAstellas Pharma Inc.
InventorsHideaki Matsuoka, Yoshinori Ishii, Kaori Matsuda, Ichiro Aramori, Hiroaki Mori
Life of this patent
Estimating the term…
Abstract
It is intended to provide a method for evaluating a pharmacological effect of a histone deacetylase (HDAC) inhibitor, comprising the steps of: (a) preparing a cell expressing CPSF5 protein; (b) contacting the cell with an HDAC inhibitor; (c) measuring the acetylation level of CPSF5 protein in the cell; and (d) comparing the acetylation level measured in the step (c) with the measured acetylation level of CPSF5 protein in a control cell that has not been contacted with the HDAC inhibitor.
Claims13
A method for evaluating a pharmacological effect of a histone deacetylase (HDAC) inhibitor, comprising the steps of:
- (a) preparing a cell expressing CPSF5 protein;
- (b) contacting the cell with an HDAC inhibitor;
- and
- (c) measuring the acetylation level of CPSF5 protein in the cell.
A method for evaluating a pharmacological effect of a histone deacetylase (HDAC) inhibitor, comprising the steps of:
- (a) administering an HDAC inhibitor to a mammal;
- (b) collecting a cell expressing CPSF5 protein from the mammal;
- and
- (c) measuring the acetylation level of CPSF5 protein in the cell.
A method for screening a histone deacetylase (HDAC) inhibitor, comprising the steps of:
- (a) preparing a cell expressing CPSF5 protein;
- (b) contacting the cell with a test substance;
- and
- (c) measuring the acetylation level of CPSF5 protein in the cell.
Dependencies are inferred from the claim text.